Patents Assigned to Merck Sharp & Dohme (I.A.) Corp.
  • Publication number: 20250000990
    Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
    Type: Application
    Filed: December 7, 2023
    Publication date: January 2, 2025
    Applicants: Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Inventors: Junyou Ge, Xiaoping Jin, Yina Diao, Jiacheng Yang, Yujie Fu, Zhijiao Qiao, Lihua Chen, Omobolaji Akala, Elliot Keith Chartash, Sarper Toker, Christian H. Poehlein, Blanca Homet Moreno
  • Publication number: 20250000744
    Abstract: An ampoule includes a body having a cavity for storing a medicament, a neck coupled to the body and defining a nozzle in communication with the cavity of the body, a removable cap coupled to the nozzle, and an anti-choking miter coupled to the removable cap, the anti-chocking miter being wider than the removable cap.
    Type: Application
    Filed: November 11, 2022
    Publication date: January 2, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ramprasad B. Halthore, Atul Karande, Derrick M. Smith
  • Patent number: 12180226
    Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: December 31, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
  • Publication number: 20240424109
    Abstract: An insulin conjugate comprising or consisting of a tetra-valent sugar cluster is described. The tetra-valent sugar cluster is provided by tetra-dentate linker having four arms, wherein each arm of the tetra-dentate linker is independently covalently linked to a ligand comprising or consisting of a saccharide, such as a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, or branched trisaccharide. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose.
    Type: Application
    Filed: November 16, 2022
    Publication date: December 26, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Pei Huo, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhiqiang Zhao, David N. Hunter, Yuping Zhu
  • Publication number: 20240425596
    Abstract: The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions. The invention also provides compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%.
    Type: Application
    Filed: September 6, 2024
    Publication date: December 26, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mark A. Brower, Chung-Jr Huang, Brian Wai Kwan, William Nicholas Napoli, Bhumit A. Patel, Nuno J. Dos Santos Pinto, Douglas Dennis Richardson, II, Sen Xu
  • Publication number: 20240424218
    Abstract: In some examples, a vial-to-syringe converter includes a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the body further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver a medicament to a patient's body.
    Type: Application
    Filed: November 1, 2022
    Publication date: December 26, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Daniel A. Bonanno, Eduardo Cristofolli, Cassie Megna, Wail A. Rasheed, Ophelia L. Wells
  • Publication number: 20240425524
    Abstract: Described herein are compounds of Formula I; and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, m, n, and p are as defined herein. The compounds of Formula I, and pharmaceutically acceptable salts thereof, act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: October 24, 2022
    Publication date: December 26, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Brandon A. Vara, Hongjun Zhang
  • Patent number: 12173026
    Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: December 24, 2024
    Assignees: Merck Sharp & Dohme LLC, MSD International GmbH
    Inventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
  • Patent number: 12171776
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: December 24, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • Patent number: 12175679
    Abstract: A method or system for training a convolutional neural network (CNN) for medical imaging analysis. The system pre-trains the CNN's encoder using a dataset of unlabeled 3D medical images. Each 3D image includes an annotated slice delineating a boundary of a lesion and multiple non-annotated 2D slices above and below the annotated slice. The system then fine-tunes the pre-trained encoder using an annotated 2D image dataset. The annotated 2D image dataset includes multiple 2D slices of lesions, each including an annotation that delineates a boundary of a corresponding lesion.
    Type: Grant
    Filed: November 28, 2023
    Date of Patent: December 24, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yiqiao Liu, Antong Chen, Gregory Goldmacher
  • Publication number: 20240416097
    Abstract: In some examples, an injector includes a base, a housing movable relative to the base, a needle unit disposed within the base, the needle unit comprising at least one piercing needle configured to pierce a pierceable membrane of a drug product container, and at least one microneedle disposed on an opposite side of the at least one piercing needle, and a driving mechanism configured and arranged to drive at least one of the drug product container and the needle unit toward another of the drug product container and the needle unit.
    Type: Application
    Filed: November 1, 2022
    Publication date: December 19, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Daniel A. Bonanno, John B. Cline, Eduardo Cristofolli, Cassie Megna, Wail A. Rasheed, Ophelia L. Wells
  • Patent number: 12168004
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: May 13, 2024
    Date of Patent: December 17, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie J. Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Publication number: 20240408188
    Abstract: The present disclosure provides, among other things, a vaccine composition that includes a squalene nanoemulsion (SNE) adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
    Type: Application
    Filed: June 6, 2024
    Publication date: December 12, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick L. Ahl, William J. Smith, Randal J. Soukup, Nicole Lea Sullivan, John Gaspar, Julie M. Skinner
  • Publication number: 20240409531
    Abstract: The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: October 10, 2022
    Publication date: December 12, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Abdellatif El Marrouni, Antonella Converso, Ashley Forster
  • Patent number: 12161721
    Abstract: The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Patrick McHugh, Michael Albert Winters, Janelle Konietzko
  • Patent number: 12162938
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • Patent number: 12162883
    Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 10, 2024
    Assignees: Merck Sharp & Dohme LLC, Merck Sharp & Dohme (UK)
    Inventors: John Y. L. Chung, Tetsuji Itoh, Jungchul Kim, Jacob Henry Waldman, Debra J. Wallace, Andrew Wood, Feng Xu, Andrew Gibson, Jeremy Peter Scott
  • Publication number: 20240398784
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: September 26, 2022
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Luis Torres, Xin Yan
  • Publication number: 20240398925
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
    Type: Application
    Filed: August 22, 2024
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
  • Publication number: 20240400571
    Abstract: Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
    Type: Application
    Filed: May 30, 2024
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Zachary G. Brill, Chen Cheng, Donna A.A.W. Hayes, Kyle S. McClymont, Rohan Rajiv Merchant, Maoqun Tian